Umfang:
Online-Ressource
ISSN:
2366-3987
Inhalt:
Abstract: The development of next‐generation biomimetic cardiovascular implants using tissue engineering concepts can address the existing shortcomings of the clinically available prostheses, offering the possibility to generate life‐long, native‐analogous constructs with self‐remodeling and regenerative capacities. Scaffolds for tissue‐engineered cardiovascular prostheses can be obtained from allogenic cell sources, that can then produce human tissue‐engineered matrices (hTEMs) in vitro. Traditionally, fetal bovine serum (FBS) is used as a universal cell growth supplement. However, concerns regarding its biosafety remain a challenge for clinical translation. The aim of this study is to develop a novel xenogeneic serum‐free approach for the manufacturing of clinical grade hTEMs. To achieve this, decellularized hTEMs are generated under xenogeneic serum‐free conditions and have subsequently demonstrated hTEMs perform similarly to the FBS‐supplemented control group in terms of extracellular matrix (ECM) composition, hemocompatibility, thrombogenicity, and calcification potential. Finally, the xenogeneic serum‐free protocol is successfully adapted to the development of hTEM‐based tissue‐engineered heart valves for the systemic circulation, showing proof‐of‐concept functionality in vitro. Overall, the data suggest the effectiveness of xenogeneic serum‐free culture method as a valid alternative to FBS for the production of hTEM for cardiovascular applications.
In:
day:14
In:
month:07
In:
year:2023
In:
extent:14
In:
Advanced therapeutics, Weinheim : Wiley-VCH Verlag, [2018]-, (14.07.2023) (gesamt 14), 2366-3987
Sprache:
Englisch
DOI:
10.1002/adtp.202300041
URN:
urn:nbn:de:101:1-2023071515135886508718
URL:
https://doi.org/10.1002/adtp.202300041
URL:
https://nbn-resolving.org/urn:nbn:de:101:1-2023071515135886508718
URL:
https://d-nb.info/1296195929/34
URL:
https://doi.org/10.1002/adtp.202300041
